<DOC>
	<DOCNO>NCT01400139</DOCNO>
	<brief_summary>The primary objective study characterize long-term safety Hydrocodone Bitartrate ( HYD ) tablets 20 120 mg once-daily subject chronic nonmalignant nonneuropathic pain .</brief_summary>
	<brief_title>Long-term Safety Once-daily Hydrocodone Bitartrate ( HYD ) Tablets For Moderate Severe Chronic Nonmalignant Nonneuropathic Pain . Includes 24-week Extension Period .</brief_title>
	<detailed_description />
	<mesh_term>Hydrocodone</mesh_term>
	<criteria>Inclusion Criteria include : Male female subject ≥ 18 year age moderate severe , chronic nonmalignant nonneuropathic pain ( lasting several hour daily ) predominant pain condition least 3 month prior screen visit ; Subjects deem investigator/medically qualify designee ( must MD DO ) appropriate candidate protocol specify , around clock HYD therapeutic regimen ; Female subject premenopausal postmenopausal less 1 year surgical sterilization ( ie , tubal ligation , partial complete hysterectomy ) must negative serum pregnancy test , nonlactating , willing use adequate reliable contraception throughout study ( eg , barrier additional spermicidal foam jelly , intrauterine device , hormonal contraception ) ; Subjects willing able compliant protocol , capable subjective evaluation ( ie pain score ) , able read understand questionnaire , willing able use electronic diary , able read , understand , sign write informed consent form English . Exclusion Criteria include : Subjects take opioid analgesic ( ) equivalent &gt; 120 mg/day oxycodone 14 day prior screen visit ; Subjects previously participate investigational hydrocodone study within 90 day prior first dose study medication ; Subjects use investigational medication hydrocodone within 30 day prior first dose study drug ; Subjects history seizure ( subject history pediatric febrile seizure may participate study ) increase intracranial pressure ; Subjects current uncontrolled depression uncontrolled psychiatric disorder ( subject control depression psychiatric disorder must stable medication ≥ 1 month prior screen visit participate study ) ; Subjects history alcohol , medication , illicit drug abuse addiction and/or history opioid abuse addiction time ; Subjects clinically unstable cardiac disease , include : unstable atrial fibrillation , symptomatic bradycardia , unstable congestive heart failure , active myocardial ischemia , indwell pacemaker ; Subjects unstable respiratory disease , opinion investigator , precludes entry study ; Subjects biliary tract disease , hypothyroidism , adrenal cortical insufficiency , medical condition , opinion investigator , inadequately treat precludes entry study ; Subjects history malignancy within past 2 year , exception basal cell carcinoma successfully treat ; Subjects evidence impair liver function upon entry study ( laboratory test value ≥ 3 time upper limit laboratory reference ( normal ) range ( ULN ) aspartate transaminase [ AST/SGOT ] alanine transaminase [ ALT/SGPT ] , value &gt; 2 time ULN alkaline phosphatase ) , total bilirubin level &gt; 1.5 time ULN , opinion investigator/medically qualified designee ( must MD DO ) , liver function impairment extent subject participate study ; Subjects evidence impair kidney function upon entry study ( ie , serum creatinine ≥ 2.5 mg/dL ) ; Subjects condition opioids contraindicate , eg , severe respiratory depression hypoxia and/or hypercapnia , severe chronic obstructive lung disease , cor pulmonale , severe bronchial asthma , paralytic ileus ; Subjects allergic hydrocodone history allergy opioids . This include subject experienced common opioid side effect ( eg , nausea , constipation ) ; Subjects receive monoamine oxidase inhibitor ( MAOIs ) take MAOIs within 2 week screen visit . Other protocolspecific inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Pain</keyword>
	<keyword>Nonmalignant pain</keyword>
	<keyword>Nonneuropathic Pain</keyword>
	<keyword>Opioid</keyword>
</DOC>